Vedanta Biosciences, Inc. Vedanta Biosciences, Inc.

  • Home
  • About
    • Overview
    • Team
    • Scientific Co-Founders and Advisors
    • Board of Directors
    • Investors
  • Pipeline
    • Overview
    • VE303
    • VE202
    • VE800
    • VE707
    • VE416
    • Partnerships
    • Intellectual Property
  • Clinical Trials
    • VE303
    • VE202
    • VE800
    • VE416
    • Expanded Access
  • Platform
    • How Our Drugs Work
    • Discovery Platform
    • Manufacturing Platform
    • Publications
  • News & Media
    • Overview
    • Press Releases
    • In The News
  • Careers
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • In The News

Press Releases

Jul 10, 2018

Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease

May 30, 2018

Vedanta Biosciences to Present at Jefferies 2018 Global Healthcare Conference

Dec 13, 2017

Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia

Dec 7, 2017

Vedanta Biosciences Announces Initiation of Phase 1a/1b Trial for New Drug Class of Rationally-Defined Bacterial Consortia Derived from the Human Microbiome

Nov 29, 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

Nov 2, 2017

CARB-X awards up to $5.4M to Vedanta Biosciences to accelerate the development of a novel human microbiome-derived treatment for deadly C. difficile bacterial infections

Nov 1, 2017

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells

May 30, 2017

Vedanta Biosciences Granted U.S. Patent Broadly Covering Methods of Treatment with Therapeutics Based on Bacterial Spore Fractions of Microbiota Obtained From Human Donors

May 16, 2017

Vedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia

Feb 16, 2017

Vedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University School of Medicine and Leiden University Medical Center

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next »
RSS Feed
© 2023 Vedanta Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap